Stocktoria

Savara Inc SVRA

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-1.13
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025-$118.8M-$101.1M$203.1M
2024-$95.9M-$89.1M-$750,000
2023-$54.7M-$51.4M-$271,000
2022-$38.1M-$34.6M-$605,000
2021-$43.0M-$40.1M$144.5M
2020$257,000-$49.6M-$39.9M$64.4M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Lowrance David LChief Financial Officer2026-06-22Tax withheld21,682$5.50
Lowrance David LChief Financial Officer2026-06-22Option exercise129,350$1.23
Lowrance David LChief Financial Officer2026-06-22Tax withheld28,928$5.50
Lowrance David LChief Financial Officer2026-06-22Option exercise56,937$1.11
Lowrance David LChief Financial Officer2026-06-22Tax withheld11,491$5.50
Lowrance David LChief Financial Officer2026-06-22Option exercise218,750$1.51
Lowrance David LChief Financial Officer2026-06-22Tax withheld60,057$5.50
Lowrance David LChief Financial Officer2026-06-22Option exercise75,000$1.59

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -1.13 (distress)

  • Working capital / assets 0.873
  • Retained earnings / assets -2.399
  • EBIT / assets -0.487
  • Equity / liabilities 4.038

Source: SEC EDGAR filings · CIK 0001160308 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.